Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | WEE1 | P30291 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284016 | 0.80 | CDK4 (0.36) | CDK4AURKAWEE1PLK1 | |
| SCHEMBL1655639 | 0.78 | RPS6KA3 (0.40) | WEE1PLK1STAT6 | |
| SCHEMBL1655648 | 0.71 | RPS6KA3 (0.41) | CDK4AURKAWEE1PLK1ROCK2 | |
| SCHEMBL1654997 | 0.68 | AURKA (0.49) | CDK4AURKAWEE1PLK1ROCK2 | |
| SCHEMBL1655091 | 0.67 | RPS6KA3 (0.49) | CDK4WEE1PLK1STAT6 | |
| SCHEMBL1655646 | 0.65 | WEE1 (0.43) | WEE1PLK1 | |
| SCHEMBL1655280 | 0.59 | RPS6KA3 (0.49) | WEE1PLK1STAT6 | |
| SCHEMBL4292091 | 0.58 | RPS6KA3 (0.49) | CDK4WEE1PLK1STAT6 | |
| SCHEMBL4288572 | 0.57 | JAK2 (0.48) | CDK4AURKASTAT6 | |
| SCHEMBL1655111 | 0.57 | AURKA (0.50) | CDK4AURKAWEE1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | CDK4 186/4885AURKA 755/4885WEE1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.